GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » PB Ratio

Sorrento Therapeutics (LTS:0L85) PB Ratio : (As of May. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-11), Sorrento Therapeutics's share price is $0.015. Sorrento Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was $-0.37. Hence, Sorrento Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Sorrento Therapeutics's PB Ratio or its related term are showing as below:

During the past 13 years, Sorrento Therapeutics's highest PB Ratio was 24.36. The lowest was 1.08. And the median was 3.64.

LTS:0L85's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.5
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Sorrento Therapeutics's average Book Value Per Share Growth Rate was -222.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sorrento Therapeutics was 103.70% per year. The lowest was -47.40% per year. And the median was 13.20% per year.

Back to Basics: PB Ratio


Sorrento Therapeutics PB Ratio Historical Data

The historical data trend for Sorrento Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics PB Ratio Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 7.89 11.30 31.94 -

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.35 28.32 - - -

Competitive Comparison of Sorrento Therapeutics's PB Ratio

For the Biotechnology subindustry, Sorrento Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's PB Ratio falls into.



Sorrento Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sorrento Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=0.015/-0.372
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Sorrento Therapeutics  (LTS:0L85) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sorrento Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (LTS:0L85) Business Description

Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines